Intravenous form of thalidomide for treating immunological disea

Details Intravenous form of thalidomide for treating immunological disea Intravenous form of thalidomide for treating immunological disea

1998-10-06

2000-09-26

Jones, Dwayne C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A01N 4340, A61K 31445, C07D40100

Patent

active

061243221

ABSTRACT:
An aqueous thalidomide solution which is suitable as a parenteral form of application of thalidomide, particularly as an intravenous form of application, for treating immunological diseases, and a method of producing the corresponding thalidomide solution.

REFERENCES:
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5434170 (1995-07-01), Andrulis
Osol, Editor of Remington's Pharmaceutical Sciences, p. 1261, Jun. 1976.
Heger et al., "Embryotoxic effects of thalidomide derivatives in the non-human promated callithrx jacchus. IV Teratogenicity of micrograms/kg doses of the EM12 enantiomers". teratogenesesis, Carcinogenesis, and Mutagenesis, 14'(3), pp. 115-122, 1999.
Krenn et al. (1993), "Improvements in Solubility and Stability of Thalidomide upon Complexation with Hydroxypropyl-beta-cyclodextrin". [Abstract]. Chemical Abstracts 118:11605, XP002089567.

Affiliated with

Also associated with

Rating

Intravenous form of thalidomide for treating immunological disea does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intravenous form of thalidomide for treating immunological disea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravenous form of thalidomide for treating immunological disea will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2100580